The novel toll-like receptor 2 agonist SUP3 enhances antigen presentation and T cell activation by dendritic cells

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Guo, Xueheng ^a   Wu, Ning ^a   Shang, Yingli ^a,b   Liu, Xin ^a,c   Wu, Tao ^a   Zhou, Yifan ^a   Huang, Jiaoyan ^a   Liao, Xuebin ^c   Wu, Li ^a  

^a Tsinghua University   (China)

^b SHANDONG AGRICULTURAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Adjuvant; Antigen presentation; Cytotoxic T lymphocyte; Dendritic cell; TLR2 agonist

Indexed keywords

ANTIGEN; CD8 ANTIGEN; CRISPR ASSOCIATED PROTEIN; CYTOKINE; IMMUNOGLOBULIN M ANTIBODY; LIPOPOLYSACCHARIDE; SUP3; THYMUS DEPENDENT ANTIGEN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INGUINAL LYMPH NODE; METASTASIS; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 85014346070     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00158     Document Type: Article

References (77)

1. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med (2013) 19(12):1597-608. doi:10.1038/nm.3409
2. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD-and toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A (2014) 111(34):12294-9. doi:10.1073/pnas.1400478111
3. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet (2009) 374(9686):301-14. doi:10.1016/S0140-6736(09)61248-4
4. Lehtinen M, Paavonen J. Sound efficacy of prophylactic HPV vaccination: basics and implications. Oncoimmunology (2012) 1(6):995-6. doi:10.4161/onci.20011
5. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines (2012) 11(2):237-56. doi:10.1586/erv.11.189
6. Zaman M, Toth I. Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships. Front Immunol (2013) 4:318. doi:10.3389/fimmu.2013.00318
7. Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, et al. Trial watch: immunostimulation with toll-like receptor agonists in cancer therapy. Oncoimmunology (2016) 5(3):e1088631. doi:10.1080/2162402X.2015.1088631
8. Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol (2014) 5:255. doi:10.3389/fimmu.2014.00255
9. Seya T, Shime H, Takeda Y, Tatematsu M, Takashima K, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer-focusing on toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci (2015) 106(12):1659-68. doi:10.1111/cas.12824
10. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol (2012) 30:1-22. doi:10.1146/annurev-immunol-100311-102839
11. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol (2013) 31:563-604. doi:10.1146/annurev-immunol-020711-074950
12. Belz GT, Nutt SL. Transcriptional programming of the dendritic cell network. Nat Rev Immunol (2012) 12(2):101-13. doi:10.1038/nri3149
13. Wu L, Liu YJ. Development of dendritic-cell lineages. Immunity (2007) 26(6):741-50. doi:10.1016/j.immuni.2007.06.006
14. Chopin M, Allan RS, Belz GT. Transcriptional regulation of dendritic cell diversity. Front Immunol (2012) 3:26. doi:10.3389/fimmu.2012.00026
15. Ginhoux F, Schlitzer A. CD11b+ DCs rediscovered: implications for vaccination. Expert Rev Vaccines (2014) 13(4):445-7. doi:10.1586/14760584.2014.893196
16. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5(10):987-95. doi:10.1038/ni1112
17. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol (2015) 16(4):343-53. doi:10.1038/ni.3123
18. Kang JY, Lee JO. Structural biology of the toll-like receptor family. Annu Rev Biochem (2011) 80:917-41. doi:10.1146/annurev-biochem-052909-141507
19. van Bergenhenegouwen J, Plantinga TS, Joosten LA, Netea MG, Folkerts G, Kraneveld AD, et al. TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J Leukoc Biol (2013) 94(5):885-902. doi:10.1189/jlb.0113003
20. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 165(10):5392-6. doi:10.4049/jimmunol.165.10.5392
21. Wooten RM, Ma Y, Yoder RA, Brown JP, Weis JH, Zachary JF, et al. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J Immunol (2002) 168(1):348-55. doi:10.4049/jimmunol.168.1.348
22. Lim YT. Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res (2015) 4(1):54-8. doi:10.7774/cevr.2015.4.1.54
23. Khan S, Bijker MS, Weterings JJ, Tanke HJ, Adema GJ, van Hall T, et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 282(29):21145-59. doi:10.1074/jbc. M701705200
24. Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S, et al. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol (2010) 40(5):1272-83. doi:10.1002/eji.200939790
25. Shen KY, Song YC, Chen IH, Chong P, Liu SJ. Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother (2014) 10(11):3241-50. doi:10.4161/hv.29275
26. Zom GG, Khan S, Britten CM, Sommandas V, Camps MG, Loof NM, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res (2014) 2(8):756-64. doi:10.1158/2326-6066.CIR-13-0223
27. Salunke DB, Connelly SW, Shukla NM, Hermanson AR, Fox LM, David SA. Design and development of stable, water-soluble, human toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. J Med Chem (2013) 56(14):5885-900. doi:10.1021/jm400620g
28. Shen KY, Song YC, Chen IH, Leng CH, Chen HW, Li HJ, et al. Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol (2014) 192(9):4233-41. doi:10.4049/jimmunol.1302850
29. Willems MM, Zom GG, Khan S, Meeuwenoord N, Melief CJ, van der Stelt M, et al. N-tetradecylcarbamyl lipopeptides as novel agonists for toll-like receptor 2. J Med Chem (2014) 57(15):6873-8. doi:10.1021/jm500722p
30. Santone M, Aprea S, Wu TY, Cooke MP, Mbow ML, Valiante NM, et al. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells. Hum Vaccin Immunother (2015) 11(8):2038-50. doi:10.1080/21645515.2015.1027467
31. Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, et al. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol (2011) 186(4):1963-9. doi:10.4049/jimmunol.1002320
32. Lee SK, Chwee JY, Ma CA, Le Bert N, Huang CW, Gasser S. Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells. Clin Cancer Res (2014) 20(13):3485-95. doi:10.1158/1078-0432.CCR-13-2522
33. Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, et al. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clin Immunol (2014) 154(1):26-36. doi:10.1016/j.clim.2014.06.004
34. Rolf N, Kariminia A, Ivison S, Reid GS, Schultz KR. Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia. Eur J Immunol (2015) 45(7):1980-90. doi:10.1002/eji.201444874
35. Chua BY, Olson MR, Bedoui S, Sekiya T, Wong CY, Turner SJ, et al. The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol Cell Biol (2014) 92(4):377-83. doi:10.1038/icb.2013.102
36. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (2014) 343(6166):84-7. doi:10.1126/science.1247005
37. Vremec D, Segura E. The purification of large numbers of antigen presenting dendritic cells from mouse spleen. Methods Mol Biol (2013) 960:327-50. doi:10.1007/978-1-62703-218-6_24
38. Belz GT. Direct ex vivo activation of T cells for analysis of dendritic cells antigen presentation. Methods Mol Biol (2010) 595:351-69. doi:10.1007/978-1-60761-421-0_23
39. Sathe P, Pooley J, Vremec D, Mintern J, Jin JO, Wu L, et al. The acquisition of antigen cross-presentation function by newly formed dendritic cells. J Immunol (2011) 186(9):5184-92. doi:10.4049/jimmunol.1002683
40. Xu H, Zhu J, Smith S, Foldi J, Zhao B, Chung AY, et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol (2012) 13(7):642-50. doi:10.1038/ni.2304
41. Shang Y, Coppo M, He T, Ning F, Yu L, Kang L, et al. The transcriptional repressor Hes1 attenuates inflammation by regulating transcription elongation. Nat Immunol (2016) 17(8):930-7. doi:10.1038/ni.3486
42. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of toll-like receptor 7 agonists. Blood (2010) 115(10):1949-57. doi:10.1182/blood-2009-08-238543
43. Zeng Y, Yi J, Wan Z, Liu K, Song P, Chau A, et al. Substrate stiffness regulates B-cell activation, proliferation, class switch, and T-cell-independent antibody responses in vivo. Eur J Immunol (2015) 45(6):1621-34. doi:10.1002/eji.201444777
44. Schreurs MW, Eggert AA, de Boer AJ, Figdor CG, Adema GJ. Generation and functional characterization of mouse monocyte-derived dendritic cells. Eur J Immunol (1999) 29(9):2835-41. doi:10.1002/(SICI)1521-4141(199909)29:09<2835::AID-IMMU2835>3.0.CO;2-Q
45. Guo X, Zhou Y, Wu T, Zhu X, Lai W, Wu L. Generation of mouse and human dendritic cells in vitro. J Immunol Methods (2016) 432:24-9. doi:10.1016/j.jim.2016.02.011
46. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol (2010) 10(6):403-14. doi:10.1038/nri2780
47. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 12(8):557-69. doi:10.1038/nri3254
48. Du J, Wu Z, Ren S, Wei Y, Gao M, Randolph GJ, et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine (2010) 28(38):6273-81. doi:10.1016/j.vaccine.2010.06.117
49. Lahiri A, Lahiri A, Das P, Vani J, Shaila MS, Chakravortty D. TLR 9 activation in dendritic cells enhances salmonella killing and antigen presentation via involvement of the reactive oxygen species. PLoS One (2010) 5(10):e13772. doi:10.1371/journal.pone.0013772
50. Fehres CM, Bruijns SC, van Beelen AJ, Kalay H, Ambrosini M, Hooijberg E, et al. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming. Eur J Immunol (2014) 44(8):2415-24. doi:10.1002/eji.201344094
51. Zhong R, Li H, Messer K, Lane TA, Zhou J, Ball ED. Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by toll-like receptor (TLR) agonists. Cancer Immunol Immunother (2015) 64(6):737-44. doi:10.1007/s00262-015-1680-x
52. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol (2001) 166(10):6099-103. doi:10.4049/jimmunol.166.10.6099
53. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 118(6):2098-110. doi:10.1172/JCI34584
54. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 11(12):807-22. doi:10.1038/nri3095
55. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol (2007) 7(7):543-55. doi:10.1038/nri2103
56. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 11(12):823-36. doi:10.1038/nri3084
57. Segura E, Villadangos JA. A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells. Traffic (2011) 12(12):1677-85. doi:10.1111/j.1600-0854.2011.01254.x
58. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 440(7085):808-12. doi:10.1038/nature04596
59. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest (2007) 117(5):1119-27. doi:10.1172/JCI31720
60. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 28:445-89. doi:10.1146/annurev-immunol-030409-101212
61. Ivanova EA, Orekhov AN. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview. Biomed Res Int (2015) 2015:327470. doi:10.1155/2015/327470
62. van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, Griffith JM, et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 106(16):6730-5. doi:10.1073/pnas.0900969106
63. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 29(9):1812-23. doi:10.1016/j.vaccine.2010.12.090
64. Cerutti A, Puga I, Cols M. Innate control of B cell responses. Trends Immunol (2011) 32(5):202-11. doi:10.1016/j.it.2011.02.004
65. Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem (2008) 15(5):506-16. doi:10.2174/092986708783503249
66. Zeng W, Eriksson EM, Lew A, Jackson DC. Lipidation of intact proteins produces highly immunogenic vaccine candidates. Mol Immunol (2011) 48(4):490-6. doi:10.1016/j.molimm.2010.10.003
67. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol (2014) 27:26-32. doi:10.1016/j.coi.2014.01.005
68. Vinuesa CG, Chang PP. Innate B cell helpers reveal novel types of antibody responses. Nat Immunol (2013) 14(2):119-26. doi:10.1038/ni.2511
69. Eriksson EM, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci (2007) 8(4):412-7. doi:10.2174/138920307781369436
70. Manoharan I, Hong Y, Suryawanshi A, Angus-Hill ML, Sun Z, Mellor AL, et al. TLR2-dependent activation of beta-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation. J Immunol (2014) 193(8):4203-13. doi:10.4049/jimmunol.1400614
71. Liu YC, Simmons DP, Li X, Abbott DW, Boom WH, Harding CV. TLR2 signaling depletes IRAK1 and inhibits induction of type I IFN by TLR7/9. J Immunol (2012) 188(3):1019-26. doi:10.4049/jimmunol.1102181
72. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol (2010) 11(5):373-84. doi:10.1038/ni.1863
73. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34(5):637-50. doi:10.1016/j.immuni.2011.05.006
74. Alves CH, Ober-Blobaum JL, Brouwers-Haspels I, Asmawidjaja PS, Mus AM, Razawy W, et al. Dendritic cell-specific deletion of beta-catenin results in fewer regulatory T-cells without exacerbating autoimmune collagen-induced arthritis. PLoS One (2015) 10(11):e0142972. doi:10.1371/journal.pone.0142972
75. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366(26):2455-65. doi:10.1056/NEJMoa1200694
76. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690
77. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515(7528):568-71. doi:10.1038/nature13954